Brilliant Violet 421™ anti-mouse Ly-6G Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

Ly-6G transfected EL-4J cell line.

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Preparation

The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.

Concentration

µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested
IHC-F - Verified

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Excitation Laser

Violet Laser (405 nm)

Application Notes

While 1A8 recognizes only Ly-6G, clone RB6-8C5 recognizes both Ly-6G and Ly-6C. Clone RB6-8C5 binds with high affinity to mouse Ly-6G molecules and to a lower extent to Ly-6C¹⁵. Clone RB6-8C5 impairs the binding of anti-mouse Ly-6G clone 1A8¹⁵. However, clone RB6-8C5 is able to stain in the presence of anti-mouse Ly-6C clone HK1.4¹⁶.

Additional reported applications (for the relevant formats) include: immunohistochemistry⁹ of frozen sections¹⁰ and paraffin-embedded sections¹¹, depletion^{4, 12-14}, and spatial biology (IBEX)^20,21. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for in vivo studies or highly sensitive assays (Cat. No. 127632, 127649, 127650, 127661 and 127662).

Application References

(PubMed link indicates BioLegend citation)

1. Fleming TJ, et al. 1993. J. Immunol. 151:2399. (FC)
2. Daley JM, et al. 2008. J. Leukocyte Biol. 83:1. (FC)
3. Dietlin TA, et al. 2007. J. Leukocyte Biol. 81:1205. (FC)
4. Daley J, et al. 2007. J. Leukocyte Biol. doi:10.1189. (Deplete) PubMed
5. Tadagavadi RK, et al. 2010. J. Immunol. 185:4904. PubMed
6. Sumagin R, et al. 2010. J. Immunol. 185:7057. PubMed
7. Guiducci C, et al. 2010. J. Exp Med. 207:2931. PubMed
8. Fujita M, et al. 2011. Cancer Res. 71:2664. PubMed
9. Van Leeuwen, et al. 2008. Arterioscler. Thromb. Vasc. Biol. 28:84. (IHC)
10. Kowanetz M, et al. 2010. P. Natl. Acad. Sci. USA 107:21248. [supplementary data] (IHC)
11. Esbona K, et al. 2016. Breast Cancer Res. 18:35. (IHC)
12. Wojtasiak M, et al. 2010. J. Gen. Virol. 91:2158. (FC, Deplete)
13. Jaeger BN, et al. 2012. J. Exp. Med. 209:565. (Deplete)
14. Wozniak KL, et al. 2012. BMC Immunol. 13:65 (FC, Deplete)
15. Ribechini E, et al. 2009. Eur. J. Immunol. 39:3538.
16. Ng LG, et al. 2011. J Invest. Dermatol. 131:2058. PubMed
17. Ma C, et al. 2012. J. Leukoc. Biol. 92:1199.
18. McCartney-Francis, N, et al. 2014. J Leukoc. Biol. 96:917. PubMed
19. Her Z, et al. 2014. EMBO Mol. Med. 7:24. PubMed
20. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
21. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed

Product Citations

1. Hutter K, et al. 2022. Front Immunol. 13:967914. PubMed
2. Wilden A, et al. 2022. Front Immunol. 13:991295. PubMed
3. Jong RM, et al. 2022. J Immunol. 208:407. PubMed
4. Minutti CM, et al. 2019. Immunity. 50:645. PubMed
5. Mansouri N, et al. 2019. JCI Insight. 4:e128060. PubMed
6. Wang L, et al. 2020. Cells. 0.458333333. PubMed
7. Radovanovic I, et al. 2014. J Immunol. 193:1290. PubMed
8. Piepke M, et al. 2021. J Neuroinflammation. 18:265. PubMed
9. Khamissi FZ, et al. 2022. Sci Adv. 8:eabm5900. PubMed
10. Han H, et al. 2021. Front Pharmacol. 12:726586. PubMed
11. Park JG, et al. 2021. iScience. 24(9):102941. PubMed
12. Gu H, et al. 2021. Immun Inflamm Dis. 9:1686. PubMed
13. Brandt S, et al. 2020. J Am Soc Nephrol. 31:2589. PubMed
14. Pan H, et al. 2020. Mol Psychiatry. . PubMed
15. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
16. Angelidis I, et al. 2019. Nat Commun. 10:963. PubMed
17. Wang LT, et al. 2021. STAR Protocols. 2(1):100337. PubMed
18. Zhang X, et al. 2022. Pharmaceutics. 14:. PubMed
19. Lee RD, et al. 2021. Nat Commun. 12:6843. PubMed
20. Ma M, et al. 2021. Front Immunol. 12:718779. PubMed
21. Green DP, et al. 2019. Neuron. 101:412. PubMed
22. Peres-Emidio EC, et al. 2022. Front Cell Infect Microbiol. 12:811474. PubMed
23. Dane EL, et al. 2022. Nat Mater. 21:710. PubMed
24. Jackson-Jones LH, et al. 2020. Immunity. 52:700. PubMed
25. Barman PK, et al. 2019. J Immunol. 202:2720. PubMed
26. Lissner MM, et al. 2020. Elife. 9:00. PubMed
27. Ajina R, et al. 2021. Cancer Immunol Res. 9:386. PubMed
28. Linehan JL et al. 2018. Cell. 172(4):784-796 . PubMed
29. Pereira JA, et al. 2020. Hum Mol Genet. 29:1253. PubMed
30. Baudoux T, et al. 2018. Sci Rep. 4.0375. PubMed
31. Morimoto A, et al. 2021. Nat Commun. 12:2136. PubMed
32. Ghandhi SA, et al. 2022. Sci Rep. 12:14124. PubMed
33. Yu Y, et al. 2022. Nat Commun. 13:6857. PubMed
34. Köhler D, et al. 2020. Nat Commun. 11:1315. PubMed
35. Hassan AO, et al. 2021. Cell Reports. 36(4):109452. PubMed
36. Vicencio JM, et al. 2022. Cell Death Dis. 13:274. PubMed
37. Liu T, et al. 2022. Front Immunol. 13:901349. PubMed
38. Macdougall CE et al. 2018. Cell metabolism. 27(3):588-601 . PubMed
39. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
40. Zeng Z, et al. 2022. Oncogene. :. PubMed
41. Li YN, et al. 2022. Nat Commun. 13:4074. PubMed
42. Pundir P, et al. 2020. Cell Host & Microbe. 26(1):114-122. PubMed
43. Murakami K, et al. 2021. Cell Reports. 34(1):108579. PubMed
44. Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed
45. Liyanage S, et al. 2016. Exp Eye Res. 151:160-70. PubMed
46. Kostadinova E, et al. 2016. Sci Rep. 6:30943. PubMed
47. Ermert D, et al. 2016. PLoS Pathog. 11: 1005043. PubMed
48. Andrade ACDSP, et al. 2021. J Virol. 95:e0127621. PubMed
49. Hasegawa T, et al. 2020. Sci Rep. 10:13480. PubMed
50. Zeng Q, et al. 2022. iScience. 25:105151. PubMed
51. Muri J, et al. 2020. eLife. 9:e53627.. PubMed
52. Xueyang Yu et al. 2017. Immunity. 47(5):903-912 . PubMed
53. Niderla-Bielinska J, et al. 2021. Int J Mol Sci. :22. PubMed
54. Wang LT, et al. 2020. Cell Rep. 32:108188. PubMed
55. Kullberg M, et al. 2015. Nanomedicine. 11: 1355-1363. PubMed
56. Olson B, et al. 2021. Brain Behav Immun. 97:102. PubMed
57. Alexander Mildner et al. 2017. Immunity. 46(5):849-862 . PubMed
58. Clemente–Casares X, et al. 2017. Immunity. 47:974. PubMed
59. Rustenhoven J, et al. 2021. Cell. 184(4):1000-1016.e27. PubMed
60. Gardner P, et al. 2017. Sci Rep. 7:40830. PubMed
61. Xu W, et al. 2021. Immunity. 54(3):526-541.e7. PubMed
62. Morein D, et al. 2021. Cells. 10: . PubMed
63. La Salvia S, et al. 2020. Am J Physiol Renal Physiol. 319:F868. PubMed
64. Fransén Pettersson N, et al. 2018. PLoS One. 13:e0203228. PubMed
65. Fleskens V, et al. 2019. Cell Rep. 26:3600. PubMed
66. Bertuzzi M, et al. 2014. PLoS Pathog. 10:1004413. PubMed
67. Harding CL, et al. 2020. Front Cell Infect Microbiol. 10:328. PubMed
68. Nepal S, et al. 2019. Proc Natl Acad Sci U S A. 116:16513. PubMed
69. Herbst S, et al. 2015. EMBO Mol Med. 30:240. PubMed
70. Zheng C, et al. 2021. J Extracell Vesicles. 10:e12109. PubMed
71. Li H, et al. 2021. J Clin Invest. 131:. PubMed
72. Xiong S, et al. 2020. J Clin Invest. 130:3684. PubMed
73. Lau A, et al. 2022. Sci Adv. 8:eabm0142. PubMed
74. Kennedy J, et al. 2014. J Exp Med. 211:2519. PubMed

RRID

AB_10897944 (BioLegend Cat. No. 127627)
AB_2562567 (BioLegend Cat. No. 127628)

Antigen Details

Structure

A 21-35 kD GPI-anchorded membrane protein

Distribution

Expressed on the majority of myeloid cells in bone marrow and peripheral granulocytes. The monoclonal antibody RB6-8C5 recognizes both Ly-6G and Ly-6C.

Cell Type

Granulocytes, Macrophages, Monocytes

Biology Area

Immunology, Innate Immunity

Antigen References

Fleming TJ, et al. 1993. J. Immunol. 151:2399.

Gene ID

546644 View all products for this Gene ID

UniProt

View information about Ly-6G on UniProt.org

Documentation

• Technical Data Sheet (pdf)
• Certificate of Analysis
• Safety Data Sheet

Reviews

Related Protocols

• Immunohistochemistry Protocol for Frozen Sections
• Cell Surface Flow Cytometry Staining Protocol

Related Pages & Pathways

Related FAQs

What is the F/P ratio range of our BV421™ format antibody reagents?

It is lot-specific. On average it ranges between 2-4.

Other Formats

Concentration & Expiration Lookup

Certificate of Analysis